New generation remedies for cancer treatments are challenging resilient cancer conditions in patients. Previously known as BOS172722, was tested in animals to study the effectiveness of paclitaxel which is kind of Chemotherapy used in treating triple-negative breast cancer, one of deadliest breast cancer known to mankind.
A human trial of this procedure is scheduled to be performed. If it is a success, it can be expanded to treat lung and ovarian cancer.
Reference Link: https://www.newscientist.com/article/2218935-anti-evolution-drug-may-help-treat-resistant-breast-cancers/
John Wiley and Sons Inc. and the Alzheimer’s Association partnered for their three publications namely Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association (A&D), Diagnosis, Assessment & Disease Monitoring (DADM), and Translational Research & Clinical Interventions (TRCI).
The journals will changeover to the Wiley Online Library platform after the publication of the November/December 2019 issue. Maria C. Carrillo, a Ph.D. holder and Chief Science officer of Alzheimer’s Association says “The Association is committed to accelerating the international effort to eliminate these devastating diseases, and these journals are an important forum for sharing the latest research about Alzheimer’s and related dementias with the global scientific community.”
Reference Link: https://newsroom.wiley.com/press-release/all-corporate-news/alzheimers-association-and-wiley-announce-publishing-partnership
HighWire has declared about their new journal hosting agreement with BMJ. HighWire has been associated with BMJ since 2005. This agreement has a five year contractual obligation and has been renewed for the third time.
They now have a joint innovation lab with BMJ and BMJ’S senior product and tech experts will be an important part of the operation. Allison Lang, Publishing Director at BMJ says, “Innovation is at the heart of what we do. The launch of our new innovation lab with HighWire means we can leverage the very best minds when it comes to technology at the forefront of digital knowledge management. Together we want to achieve new developments that not only enable provision of healthcare knowledge globally, but set new standards of excellence for STM publishing.”
Reference Link: https://www.businesswire.com/news/home/20190923005542/en/HighWire-Strengthens-Relationship-BMJ-Delivering-Improved-Hosting
Experimental Results, a new Cambridge University journal has been launched to take on problems faced by research scholars. This will allow unpublished research to use a platform and it will also make peer review faster.
Fiona Hutton, head of STM Open Access Publishing says “Scholarly communication isn’t really reflective of the research process, because the focus is on publishing a concise narrative. The reality is that research results are often confusing, inconclusive, or don’t fit a narrative.”
Reference Link: https://www.cambridgenetwork.co.uk/news/new-journal-aims-tackle-biggest-problems-scholarly-communication
BMJ launches BMJ Surgery Interventions & Health Technologies open access journal to its expanding portfolio that houses more than 70 specialist journals. BMJ SIT is dedicated to the latest advancements in the field of surgical therapeutic devices and interventional procedures. Its aim is to encourage high quality scientific knowledge and innovations in the field. The title will offer an impactful international platform for both early and later-stage clinical studies. It will be focusing on fast submissions and review processes with continuous publication online.
Professor Art Sedrakyan, of Weill Cornell Medical College New York said “Our ambition is to publish high-quality evidence at all stages of the life cycle of innovative as well as widely adopted surgical therapeutic devices and interventional procedures. It is my hope that this innovation in healthcare interventions will improve not only patient outcomes but the overall quality of care and treatment patients receive.”
Reference Link: https://www.bmj.com/company/newsroom/bmj-launches-new-open-access-journal-on-complex-healthcare-interventions/
Springer Publishing Company has moved its manuscript submission and peer review system to ScholarOne. This agreement covers all of Springer Publishing Company’s journals as well as Publons Reviewer Recognition and Reviewer Connect services. Springer Publishing will have access to the new AI-controlled article scanning features that ScholarOne has.
Adam Etkin, editor for journals at Springer Publishing Company said “When considering a new provider for our peer review system, it was important to choose an innovative and publisher-independent organization to handle the most important services for our research community.”
Reference Link: https://www.researchinformation.info/news/springer-moves-scholarone
Donepezil, a drug that is commonly used in treating Alzheimer’s disease and many forms of dementia has been associated with increased risk of hospitalization for rhabdomyolysis, a painful condition of muscle breakdown.
Rhabdomyolysis may also result in kidney-related diseases as well. Doctors suggest that the risk is low yet a statistically significant one.
Reference Link: https://scitechdaily.com/commonly-used-drug-for-alzheimers-disease-doubles-risk-of-hospitalization/
Toronto Innovation Acceleration Partners (TIAP) – formerly known as MaRS Innovation- and Amgen are collaborating to jointly fund emerging technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations will identify promising medical research conducted by the scientific community of Toronto and will further determine which ones have the potential to disrupt the medical industry. Rafi Hofstein, CEO of TIAP, expects that with Amgen’s philosophical and financial backing, the organization will be able to promote science and innovation reach its potential in the marketplace. Moreover, the joint venture will enrich TIAP’s presence in Canada as well as open up a meaningful dialogue with all stakeholders in the local health care system.
Reference Link: https://www.biospace.com/article/toronto-innovation-acceleration-partners-announces-strategic-partnership-with-amgen/
Megajournals have witnessed a decline because publication speed has with high acceptance rates. “Megajournal publishers clearly have yet to persuade many researchers that their approach adds significant value to the scholarly communications ecosystem,” says information scientist Stephen Pinfield from the University of Sheffield in the United Kingdom.
They witness decline in submissions because of newer journals with more flexible business modules are offered to researchers. A lot of these issues faced by the megajournals have also a lot to do with staffing issues as well. It seems newer and niche publishers are seeing most of the business.
Reference Link: https://www.sciencemag.org/news/2019/09/open-access-megajournals-lose-momentum-publishing-model-matures
In Japan, scientists for the first time have treated a damaged cornea by using induced pluripotent stem cells (iPS) which is reprogrammed from adult cells.
It is a process that converts the cells into embryonic-like cells which can further develop into any type of human cells such as nerve, pancreatic, liver, and corneal cells. While iPS cells have great potential to treat many conditions, they are yet to make from just testing in laboratories to practicing in clinics.
Reference Link: https://www.medicalnewstoday.com/articles/326243.php